Stock comparison
Haemonetics
TG Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HAE
Haemonetics
Market cap
$2.88B
Sector
Healthcare
TGTX
TG Therapeutics
Market cap
$6.01B
Sector
Healthcare
Overall winner
Haemonetics HAE
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HAE | TGTX | Winner |
|---|---|---|---|
| Warren Buffett | 70B | 49D | HAE |
| Benjamin Graham | 85A | 62D | HAE |
| Philip Fisher | 60C | 54C | HAE |
| Peter Lynch | 54C | 80A | TGTX |
| Joel Greenblatt | 31F | 63C | TGTX |
| Charlie Munger | 54D | 52D | HAE |
| Terry Smith | 55D | 44D | HAE |
Side-by-side metrics
| Metric | HAE | TGTX |
|---|---|---|
| Market cap | $2.88B | $6.01B |
| P/E (TTM) | 24.8x | 13.3x |
| EV/EBIT | 14.1x | 55.3x |
| ROIC (TTM) | 8.37% | 11.13% |
| Gross margin | 55.74% | 83.04% |
| Net margin | 7.29% | 65.95% |
| Revenue CAGR 5y | 7.65% | 2.1% |
| EPS CAGR 5y | 24.62% | - |
| Debt / Equity | 1.5x | 1.3x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HAE leads on
- EV/EBIT14.1xvs 55.3x+74%
TGTX leads on
- Revenue CAGR 5y2.1%vs 7.65%+96%
- Net margin65.95%vs 7.29%+89%
- Market cap$6.01Bvs $2.88B+52%
- P/E (TTM)13.3xvs 24.8x+46%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.